Stockscreener 앱 받기
7.54
5.50%
-0.43
전일 마감가:
$7.97
열려 있는:
$7.9
하루 거래량:
1.29M
Relative Volume:
0.72
시가총액:
$2.39B
수익:
$2.68B
순이익/손실:
$-184.45M
주가수익비율:
-11.08
EPS:
-0.6805
순현금흐름:
$229.23M
1주 성능:
-1.16%
1개월 성능:
+2.06%
6개월 성능:
-8.71%
1년 성능:
+11.42%
1일 변동 폭
$7.465
$8.01
1주일 범위
$7.155
$8.02
52주 변동 폭
$6.29
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
명칭
Amneal Pharmaceuticals Inc
전화
908-947-3120
주소
400 Crossing Boulevard, 3rd Floor, Bridgewater
AMRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
7.535 | 2.39B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
157.63 | 68.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.36 | 47.71B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.62 | 46.12B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.52 | 18.55B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.47 | 13.40B | 2.76B | 1.11B | 898.10M | 22.77 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-09-06 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | 업그레이드 | Goldman | Sell → Buy |
| 2020-12-14 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-12-14 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-07-27 | 개시 | Goldman | Sell |
| 2020-05-12 | 업그레이드 | Guggenheim | Sell → Neutral |
| 2019-12-12 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-07 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | 개시 | Barclays | Equal Weight |
| 2019-05-21 | 업그레이드 | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | 개시 | SunTrust | Buy |
| 2019-03-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | 다운그레이드 | SunTrust | Buy → Hold |
| 2018-08-13 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | 개시 | Morgan Stanley | Overweight |
| 2018-06-22 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Amneal Pharmaceuticals Inc 주식(AMRX)의 최신 뉴스
Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2025 Earnings Call Transcript - Insider Monkey
Amneal Pharmaceuticals Inc (AMRX) Q1 2025 Earnings Call Highlights: Strong Growth and Strategic ... By GuruFocus - Investing.com Canada
Amneal Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks
Amneal: Q1 Earnings Snapshot - MySA
Amneal Q1 2025 slides: Revenue up 5%, EPS surges 50% amid strategic shift - Investing.com Nigeria
Drug Maker Amneal Highlights Strong Commercial Uptake For Parkinson's Drug But Q1 Earnings Are Mixed - Benzinga
Earnings call transcript: Amneal Pharmaceuticals Q1 2025 beats EPS forecasts - Investing.com Nigeria
Amneal Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AMRX) - Seeking Alpha
Amneal (AMRX) Reports Strong Start in 2025 Despite Missing Reven - GuruFocus
Amneal Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Amneal Pharmaceuticals Q1 2025: Revenue Miss but Profit Beats ExpectationsNews and Statistics - IndexBox
Amneal Pharma A earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Amneal Pharma Swings To Profit In Q1, Beats Estimates; Affirms FY25 Guidance - Nasdaq
Amneal Reports First Quarter 2025 Financial Results - BioSpace
Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates - Yahoo Finance
Amneal Pharmaceuticals Reports Strong Q1 2025 Financial Results - TipRanks
Amneal Pharmaceuticals misses revenue estimates, stock falls 3% By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise; 2025 Outlook Affirmed - marketscreener.com
Amneal (NASDAQ:AMRX) Misses Q1 Sales Targets, Stock Drops 11.3% - Yahoo Finance
Amneal Pharmaceuticals misses revenue estimates, stock falls 3% - Investing.com
(AMRX) Amneal Pharmaceuticals Forecasts Fiscal Year 2025 Adjusted EPS Range $0.65$0.70 - marketscreener.com
Earnings Flash (AMRX) Amneal Pharmaceuticals Posts Q1 Revenue $695.4M, vs. FactSet Est of $714.8M - marketscreener.com
Amneal (AMRX) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Despite recent sales, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) insiders remain the largest stockholders with 49% ownership - simplywall.st
Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
2 Reasons to Avoid AMRX and 1 Stock to Buy Instead - Yahoo Finance
Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.
Amneal Pharmaceutical LLC Issues a Nationwide Recall of Ropivacaine Hydrochloride Injection, USP 500mg/100mL, Due to the Potential Presence of Particulate Matter - usrecallnews.com
Even though Amneal Pharmaceuticals (NASDAQ:AMRX) has lost US$78m market cap in last 7 days, shareholders are still up 125% over 5 years - Yahoo Finance
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
Lobbying Update: $60,000 of AMNEAL PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
Amneal donates $1.5M this Parkinson’s Awareness Month - NJBIZ
NY AG reaches $270M multistate opioid settlement with Amneal Pharmaceuticals - Class Action Lawsuits
Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month - BioSpace
Amneal's $1.5M Donation Makes Parkinson's Medications More Accessible for Thousands - Stock Titan
Amneal to Report First Quarter 2025 Results on May 2, 2025 - Bluefield Daily Telegraph
Amneal Launches Boruzu for Multiple Myeloma and Mantle Cell Lymphoma - Clinical Oncology News
Amneal’s CREXONT improves sleep in Parkinson’s patients By Investing.com - Investing.com South Africa
Amneal's Combination Drug Shows Improved Sleep Quality In Parkinson's Disease Patients - Benzinga
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease - BioSpace
Amneal Announces New Data From Phase 3 Study - marketscreener.com
Amneal’s CREXONT improves sleep in Parkinson’s patients - Investing.com
Breakthrough: New Parkinson's Drug Shows Major Sleep Quality Gains in Phase 3 Trial - Stock Titan
Amneal Boruzu Subcutaneous Formulation Launch - Specialty Pharmacy Continuum
Amneal Pharmaceuticals (AMRX) Expands Coverage for Parkinson's D - GuruFocus
Amneal Pharmaceuticals Inc (AMRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.77%
0.17%
자본화:
|
볼륨(24시간):